An initiative of the FDA's Oncology Center of Excellence, Project Patient Voice will serve as a source of publicly available information describing patient-reported symptoms from cancer trials for commercially available treatments. This patient-reported data has historically been analyzed by the FDA during the drug approval process, but it is largely inaccessible to the public, as it's rarely included in product labeling, the FDA said.

The Project Patient Voice website will include a list of cancer clinical trials that have patient-reported symptom data available. A table of patient-reported systems will be included with each trial. What's more, users can select patient-reported symptoms to create a series of bar and pie charts that describe symptoms at baseline and over the first six months of treatment, according to the FDA.

As a result, users can gain insights into side effects not currently listed in standard FDA safety tables, including existing symptoms before treatment begins, symptoms over time, and the subset of patients who did not have a particular symptom prior to starting treatment, the FDA said.

Only one trial will be included during the first phase of the pilot website while the FDA seeks public feedback on how the information is presented and then considers potential improvements. The FDA and the American Society of Clinical Oncology (ASCO) will co-host a virtual public workshop on July 17 to receive public feedback.

The FDA noted that AstraZeneca is the first company to provide patient-reported outcome data for Project Patient Voice from one of their FDA-approved drugs. The firm has also collaborated with the FDA to identify methods for displaying information in a way that's informative to healthcare professionals and patients, the FDA said.

Accelerating COVID-19 drug repurposing with computers, organ chips
The U.S. Defense Advanced Research Projects Agency (DARPA) has awarded the Wyss Institute for Biologically Inspired Engineering at Harvard University...

FDA revokes EUA for chloroquine, hydroxychloroquine
The U.S. Food and Drug Administration (FDA) on June 15 revoked the emergency use authorization (EUA) for chloroquine phosphate and hydroxychloroquine...

FDA researchers explore vaccine responses to SARS-CoV-2 antigens
Different proteins associated with SARS-CoV-2, the virus that causes COVID-19, generate unique immune responses when given to rabbits as immunizations,...

FDA researchers describe lessons learned from COVID-19 immunology
Key immunological factors underlying the clinical stages of COVID-19 that could be targeted by therapeutic drugs were outlined in a review by U.S. Food...

FDA issues guidance to accelerate COVID-19 therapy trials
With over 140 clinical trials of potential COVID-19-related drugs and biological products underway, the U.S. Food and Drug Administration (FDA) issued...